Bhargava S, Agrawal G P
Department of Pharmaceutical Sciences, Dr. H.S. Gour University Sagar (M.P.) 470003, India.
Curr Drug Deliv. 2008 Jan;5(1):1-6. doi: 10.2174/156720108783330998.
Cefpodoxime proxetil (CPDX-PR) is an oral cephalosporin antibiotic with poor aqueous solubility and bioavailability. Effect of beta-cyclodextrin on aqueous solubility and dissolution rate of cefpodoxime proxetil was evaluated by the formation of solid inclusion complexes in 1:2 molar ratio of drug: cyclodextrin. Phase solubility study was carried out whereby a typical B's type curve was obtained thus, indicating a 1:2 stoichiometric ratio for optimum complex formation. Solid inclusion complexes in 1:2 molar ratios were prepared by using methods such as physical mixture, solvent evaporation and freeze drying. Prepared complexes were characterized by fourier transform infrared spectroscopy (FT-IR) differential scanning calorimetry (DSC), powder x-ray diffraction (PXRD) and scanning electron microscopy (SEM). Results of in vitro studies appraised of an increased solubility and dissolution rate of cefpodoxime proxetil on complexation with beta- cyclodextrin (P < 0.05) as compared to CPDX-PR alone. Amongst the complexes prepared by different methods, the complex prepared by freeze drying showed the highest dissolution rate (P< 0.01). The in vitro antimicrobial activity of cefpodoxime proxetil and its freeze dried complex (1:2) was studied against both antibiotic-susceptible and antibiotic-resistant clinical isolates of Neisseria gonorrhoeae. The freeze dried complex (1:2) inhibited all penicillin-susceptible strains and penicillinase-producing strains at 0.015 microg/ml concentration. Chromosomally resistant strains which were not responsive to penicillin were inhibited by the complex at 0.125 microg/ml concentration. The study revealed that complexation of cefpodoxime proxetil with beta-cyclodextrin effectively enhanced the aqueous solubility and in vitro antibacterial activity.
头孢泊肟酯(CPDX-PR)是一种口服头孢菌素类抗生素,其水溶性和生物利用度较差。通过以药物:环糊精1:2的摩尔比形成固体包合物,评估了β-环糊精对头孢泊肟酯水溶性和溶解速率的影响。进行了相溶解度研究,从而获得了典型的B型曲线,这表明形成最佳络合物的化学计量比为1:2。通过物理混合、溶剂蒸发和冷冻干燥等方法制备了1:2摩尔比的固体包合物。通过傅里叶变换红外光谱(FT-IR)、差示扫描量热法(DSC)、粉末X射线衍射(PXRD)和扫描电子显微镜(SEM)对制备的络合物进行了表征。体外研究结果表明,与单独的CPDX-PR相比,头孢泊肟酯与β-环糊精络合后其溶解度和溶解速率增加(P < 0.05)。在通过不同方法制备的络合物中,冷冻干燥制备的络合物显示出最高的溶解速率(P < 0.01)。研究了头孢泊肟酯及其冷冻干燥络合物(1:2)对淋病奈瑟菌抗生素敏感和耐药临床分离株的体外抗菌活性。冷冻干燥络合物(1:2)在0.015μg/ml浓度下抑制所有青霉素敏感菌株和产青霉素酶菌株。对青霉素无反应的染色体耐药菌株在0.125μg/ml浓度下被该络合物抑制。该研究表明,头孢泊肟酯与β-环糊精络合有效地提高了水溶性和体外抗菌活性。